Media Center
- No
-
Category
- Show all
- Press Release
- News Article
- PR Video
- CEO Story
- Title
- Author
- Time uploaded
- Views
- Likes
- 188
- Press Release
- Press Release PharmAbcine Receives HREC Approval in Australia for the Phase 1a/b Trial of Its Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)
- PharmAbcine
- 18 Sep 2023
- Views2248
- 0
- 187
- Press Release
- Press Release PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD
- PharmAbcine
- 24 May 2023
- Views3004
- 0
- 186
- CEO Story
- CEO Story IMAPAC Singapore Biopharma Awards 2023
- PharmAbcine
- 24 Mar 2023
- Views2452
- 0
- 185
- CEO Story
- CEO Story Clinical Trials Festival Asia 2023 - IMAPAC
- PharmAbcine
- 20 Jan 2023
- Views4148
- 0
- 184
- CEO Story
- CEO Story Dr. Yoo to participate in the 41th Annual J.P. Morgan Healthcare Conference
- PharmAbcine
- 27 Dec 2022
- Views2686
- 0
- 183
- Press Release
- Press Release PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)
- PharmAbcine
- 13 Dec 2022
- Views3049
- 0
- 182
- CEO Story
- CEO Story PharmAbcine to Participate in the 41th Annual J.P. Morgan Healthcare Conference and Biotech Showcase™ 2023 and JPM@BIO
- PharmAbcine
- 9 Dec 2022
- Views2173
- 0
- 181
- Press Release
- Press Release PharmAbcine to Participate in the 41th Annual J.P. Morgan Healthcare Conference and Biotech Showcase™ 2023 during JPM Week
- PharmAbcine
- 9 Dec 2022
- Views1892
- 0
- 180
- CEO Story
- CEO Story Jefferies 2022 London Healthcare Conference
- PharmAbcine
- 25 Oct 2022
- Views1609
- 0
- 179
- Press Release
- Press Release PharmAbcine to participate in Jefferies 2022 London Healthcare Conference
- PharmAbcine
- 25 Oct 2022
- Views1483
- 0